var path='http://www.tickertech.com'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("selfdirectedinvestor.com") > 0) || (ref.indexOf("128.241.244.123") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("marketnewsvideo.mobi") > 0) || (ref.indexOf("206.71.145.70") > 0) || (ref.indexOf("206.71.145.73") > 0) || (ref.indexOf("206.71.145.76") > 0) || (ref.indexOf("selfdirectedinvestor.mobi") > 0) || (ref.indexOf("google.") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\; Basic Quotes - VRTX | \n'); } if (allow) { document.write('Monday, May 6, 10:20 AM\n'); } if (allow) { document.write(' |
\n'); } if (allow) { document.write('
Please click on a symbol to receive a detailed quote. At least 20 min. delay. | \n'); } if (allow) { document.write(' \; | \n'); } if (allow) { document.write('
Symbol | \n'); } if (allow) { document.write('Last Trade | \n'); } if (allow) { document.write('Change | \n'); } if (allow) { document.write('Volume | \n'); } if (allow) { document.write('More Info | \n'); } if (allow) { document.write('||||||
---|---|---|---|---|---|---|---|---|---|---|
VRTX | \n'); } if (allow) { document.write('10:01 a.m. | \n'); } if (allow) { document.write('402.50 | \n'); } if (allow) { document.write('
| \n'); }
if (allow) { document.write('
| \n'); }
if (allow) { document.write('135,498 | \n'); } if (allow) { document.write('\n'); }
if (allow) { document.write('detailed quote \n'); }
if (allow) { document.write('chart news profile \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \n'); }
if (allow) { document.write('
\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |  \;symbol lookup \; | \n'); } if (allow) { document.write(' \; Find more stocks like \; | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' |
4/26 - 4:13 PM \; \; | \n'); } if (allow) { document.write('ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &\; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN | \n'); } if (allow) { document.write('
4/23 - 1:00 AM \; \; | \n'); } if (allow) { document.write('VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX\'S CELL THERAPIES FOR TYPE 1 DIABETES | \n'); } if (allow) { document.write('
4/18 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | \n'); } if (allow) { document.write('
4/12 - 5:17 PM \; \; | \n'); } if (allow) { document.write('ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &\; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN | \n'); } if (allow) { document.write('
4/10 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | \n'); } if (allow) { document.write('
4/10 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | \n'); } if (allow) { document.write('
4/9 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Vertex to Announce First Quarter 2024 Financial Results on May 6 | \n'); } if (allow) { document.write('
4/1 - 11:01 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | \n'); } if (allow) { document.write('
4/1 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease | \n'); } if (allow) { document.write('
3/21 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | \n'); } if (allow) { document.write('
2/20 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Vertex to Participate in Upcoming Investor Conferences | \n'); } if (allow) { document.write('
2/13 - 1:59 AM \; \; | \n'); } if (allow) { document.write('European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™\; (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | \n'); } if (allow) { document.write('
2/5 - 4:07 PM \; \; | \n'); } if (allow) { document.write('Vertex Reports Fourth Quarter and Full Year 2023 Financial Results | \n'); } if (allow) { document.write('
2/5 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis | \n'); } if (allow) { document.write('
1/30 - 6:28 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain | \n'); } if (allow) { document.write('
more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' | |
\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write(' \n'); } if (allow) { document.write(' Private-label branded pages powered by TickerTech.com. \n'); } if (allow) { document.write(' Copyright ©\; 2024 Ticker Technologies Inc., \n'); } if (allow) { document.write('All Rights Reserved. Quote data is at least 20 minutes delayed. \n'); } if (allow) { document.write('NYMEX/COMEX data is at least 30 minutes delayed. Please read other important \n'); } if (allow) { document.write(' disclaimer information.\n'); } if (allow) { document.write(' | \n'); } if (allow) { document.write('